NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday 14 April 2022, 9:30am

**Location:** via Zoom

## Attendees

Committee members present

1. Dr Charles Crawley (Chair) Present for all items
2. Baljit Singh (Vice-chair) Present for all items
3. Denise Bryceland Present for all items
4. Professor Iolo Doull Present for all items
5. Dr James Fotheringham Present for items 1 – 5.3
6. Dr Mark Glover Present for all items
7. Dr Veline L’Esperance Present for items 1 – 4.3.2
8. Professor Nicholas Latimer Present for all items
9. Dr Rhiannon Owen Present for all items
10. Anna Pracz Present for all items
11. Gabriel Rogers  Present for all items
12. Dr Stephen Smith Present for all items
13. Dr Toby Smith Present for all items
14. Professor Nicky Welton Present for all items
15. Nigel Westwood Present for all items
16. Tony Wootton Present for all items

NICE staff present

Richard Diaz, Associate Director Present for all items

Daniel Davies, Project Manager Present for all items

Carl Prescott, HTA Adviser Present for items 1 – 4.3.2

Summaya Mohammad HTA Analyst Present for items 1 – 4.3.2

Catherine Spanswick, HTA Analyst Present for all 5 – 5.3

Heather Stegenga, HTA Analyst Present for items 5 – 5.4.2

Rachel Ramsden, HTA Analyst Present for items 1 – 4.1.3

Philip Williams, Business Analyst, RIA Present for items 1- 4.3.2

Emily Eaton-Turner, Technical Analyst, Commercial Risk Present for items 5 – 5.4.2

Korin Knight, Senior Medical Editor Present for all items

Catherine Pank, Assistant Project Manager, COT Present for all items

Lucinda Evans, Coordinator, MIP Present for all items

Gemma Smith, Coordinator, COT Present for items 5 – 5.4.2

Emma Gordon, Administrator, TA Present for all items

External assessment group representatives present

Ash Bullement, PenTAG Present for items 1 – 4.2.1

GJ Melendez Torres, PenTAG Present for items 1 – 4.2.1

Ben Wijen, Kleijnen Systematic Reviews (KSR) Present for items 5 – 5.3

Robert Wolff, Kleijnen Systematic Reviews (KSR) Present for items 5 – 5.3

Clinical experts present

Dr Kieran McCafferty, Consultant Nephrologist, Barts Health NHS Trust. Present for items 1 – 4.1.3

Professor Stephen Bain, Professor of Medicine (Diabetes), University of Swansea Medical School . Present for items 1 – 4.1.3

Dr Paul Cooper, Consultant Neurologist, Greater Manchester Neurosciences Centre. Present for items 5 – 5.3

Professor Helen Cross, The Prince of Wales’s Chair of Childhood Epilepsy, UCL Great Ormond Street Institute of Child Health. Present for items 5 – 5.3

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Stuart Williams, Laura Bojke and Peter Wheatley-Price.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Thursday 17 March 2022

### Appraisal of Finerenone for treating chronic kidney disease in people with type 2 diabetes [ID3773]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Bayer.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Professor Nicholas Latimer declared a non-financial, professional interest as he is a member of the ScHARR team for a research project investigating methods for adjusting for treatment switching in clinical trials, funded by Merck, Sharpe and Dohme. This is not drug or appraisal specific and is about developing methods. Merck, Sharpe and Dohme are listed as a comparator. It was agreed that this declaration would not prevent Professor Latimer from participating in the discussion.
* Gabriel Rogers declared a non-financial, professional interest as he is an ex-employee of NICE and worked on the health economics content of the NICE guidance NG28 Type 2 Diabetes. It was agreed that this declaration would not prevent Mr Rogers from participating in the discussion.
* Dr Kieran McCaffery declared a direct financial interest as he has received speaker honoraria, and provided consultancy for Bayer, AstraZeneca, Vifor Fresenius, Napp, Pharmacosmos, Oncacre. Dr McCaffery also declared a direct non-financial interest because he is National Chief investigator for the FIGARO, FIDELIO and DEFINDER studies, and a grant holder for AstraZeneca and Chiesi. Dr McCaffery also declared an indirect non-financial interest because he is a member of the UK Kidney association, the European Renal Association and the American society of Nephrology. It was agreed these declarations would not prevent Dr McCafferty from providing expert advice in this discussion.
* Professor Stephen Bain declared a direct financial interest because in the past three years, he has had one contact with Bayer (an advisory board). He has also had contacts with the three of the companies that produce SGLT2 inhibitors (Astra Zeneca, Boehringer Ingelheim & Napp) but these are not competing with Finerenone in this clinical space. It was agreed that these declarations would not prevent Professor Bain from providing expert advice in this discussion.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by the Lead Team: Gabriel Rogers (cost), Mark Glover (clinical) and Nigel Westwood (lay).
  1. Part 2a – Closed session (members of the public, company representatives, and professional experts were asked to leave the meeting).
     1. The committee discussed confidential information submitted for this item.
  2. Part 2b – Closed session (external assessment group representatives were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Document (FAD.) The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10820>

### Appraisal of Fenfluramine for treating seizures associated with Dravet syndrome [ID1109]

* 1. Part 2a – Closed session (members of the public were not present.)
  2. The chair welcomed the invited professional experts, external assessment group representatives, and company representatives from Zogenix.
  3. The Chair asked all committee members, professional experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Peter Wheatley-Price declared a direct financial interest prior to the meeting, as Takeda completed a deal in March 2021 to purchase Soticlestat for the treatment of Dravet and Lennox-Gastaut syndrome. The molecule is commencing phase 3 trials now and is due for launch in 2023 or beyond. It was agreed that this declaration would prevent Peter Wheatley-Price from taking part in this discussion.
* Professor Helen Cross declared an indirect financial interest, having been an investigator in clinical trials for Zogenix, GW Pharma and Marinius, for which remuneration was made to their organisations department, and not received personally. Furthermore, Professor Cross has spoken at educational symposia sponsored by Zogenix and Biocodex, at the annual British Paediatric Neurology Association January 2022, for which remuneration was paid to their department, and not received by Professor Cross personally. It was agreed that these declarations would not prevent Professor Cross from providing expert advice in this discussion.
  1. Part 2b – Closed session (company representatives, professional experts, external assessment group representatives were asked to leave the meeting.)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Document (FAD.) The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10373>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Thursday 12 May 2022 and will start promptly at 09:30am.